Melexis MLX90130 Manual

Features and Benefits
 Conforms with ISO/IEC 14443 A and B
 Conforms with ISO/IEC 15693
 Conforms with ISO/IEC 18000-3 mode 1
 High speed communication (up to 848kbit/s)
 Standard SPI/UART interfaces
 Built-in Field and TAG detectors
Ordering Information
Part Code Temperature Code
MLX90130 S (-20°C to 85°C)
MLX90130 S (-20°C to 85°C)
MLX90130 R (-40°C to 105°C)
MLX90130 R (-40°C to 105°C)
Functional Diagram
MLX90130
RX1
TX1
Analog Digital
TX2
section section
RX2
Figure 1: MLX90130 functional diagram
Description
The MLX90130 is a 13.56MHz, fully integrated,
multi-protocol RFID transceiver IC. It has been
designed to handle sub-carrier frequencies from
106 to 848 kHz and baud rates up to 848kbit/s.
3901090130
Rev. 004
Package Code
LQ (Lead free QFN 5x5 32 leads)
LQ (Lead free QFN 5x5 32 leads)
LQ (Lead free QFN 5x5 32 leads)
LQ (Lead free QFN 5x5 32 leads)
microcontroller
SPI/UART
Page 1 of 37
13.56MHz RFID Transceiver
Application Examples
 Medical applications such as post-surgery
monitoring, glucose
identification
 Access control readers
 Industrial automation. Monitoring of goods
during manufacturing and work-in-progress
Option Code Packing Form Code
AEA-000
AEA-000
AEA-000
AEA-000
The dual driver architecture of the MLX90130
requires minimal external support components
and allows the transmitter to provide up to 300
milliwatts RF power to an appropriate antenna
load. This delivered power is suitable for most
short to mid-range applications.
The digital section of the MLX90130 handles the
low protocol layers from API to physical layer
using advanced bit and frame encoding/decoding
functions. It contains a digital demodulator based
on sub-carrier detection and a programmable
bit/symbol encoder/decoder. It also encodes and
decodes the start and stop bits, parity bits, extra
guard time (EGT), start and end of frame
(SOF/EOF) and CRC.
Its 528 byte buffer handles an entire RFID frame.
The SPI/UART communication ports guarantee
easy interface with
microcontrollers.
MLX90130
metering and drug
RE
TU
RE
TU
the majority
Jan-2014
of